Hosted by BiotechTV · 🇺🇸 US · EN-US · 429 episodes
Established thought leaders with verified media credentials.
This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.
BiotechTV hosts BiotechTV - News, a science show with 429 episodes published.
The lead two programs, which target TLR7/8 and PARP1, have data at ASCO and were licensed with the idea of laying the foundation for clinical expertise at Eikon. Another clinical program, a WRN helicase inhibitor, is the
Dr. Mark Goldsmith of Revolution Medicines describes the benefit seen by advanced patients who received the pancreatic cancer pill daraxonrasib vs those in a control group of investigator's choice standard-of-care chemot
Co-Founder & CEO Natalie Mount discusses the raise, and explains why she believes gamma delta T-cell engagers have advantages over CD3s. After presenting preclinical data at the recent AACR annual meeting, the lead EGFR
Philip Astley-Starke describes the timeline of development of this oncolytic immunotherapy, his impression of FDA's review process and decisions around it, and the status of where the treatment stands today.
CSO Robert Allen describes Invivyd's approach and why antibodies can be a good approach, especially as it relates to being resistant to viral evolution. He walks us through the science and some potential use cases.
Co-Founder & CEO Michel Maharbiz describes the idea behind this brain-computer interface (BCI), which is not yet in human trials. While cautioning that much work and learning lies ahead, he sees the possibility that such
He describes his work in tropical disease, and how climate change has been elevating it in areas like the Gulf Coast of the United States. Plus, the importance of elevating scientists, what he has found works best for co
He shares his thoughts on the data, the competitive profile of this IL-2 Treg therapy vs JAK inhibitors, and how the overall platform looks for other I&I conditions.
Co-Founder and CEO Serge Saxonov walks us through the platform, which can process up to 800 whole-transcriptome samples per year (1 cm² each) on a single instrument, scaling to thousands of samples per year for targeted
Plus, discussions on key trial readouts outside of obesity: eplontersen, Lp(a), oral IL-23, and milvexian.
He discusses Praxis, Insmed, Ionis, PTC Therapeutics, Rapport, and United Therapeutics.
After experiencing a setback last year with Korro's LNP delivered alpha-1 antitrypsin deficiency program, he describes learnings from that experience and how Korro has new momentum with a galNAc delivered approach target
He describes both the biomarker and functional benefits seen in the December data for the company's next-generation exon 51 skipping therapy.
He reminds us of the unmet need for this type of therapy and discusses the planning that Vera has been doing ahead of the decision date.
He describes physician, patient, and payor feedback from this closely watched launch. Plus, praliciguat, and why Akebia bought a targeted complement inhibitor from Q32 Bio.
He discusses the INHBE data and the market reaction to it, which he believes is due to misconceptions about the patient population, and the next steps for this program. Plus, an AATD presentation that will happen next mo
CEO Alice Reicin walks us through recent data and guides for what is next in this patient population. Plus, an upcoming healthily volunteer readout for a HHT program and how it might translate to patients in future trial
CEO James Helliwell describes Eupraxia's platform and how it differs from other extended release technologies. Plus, Eosinophilic Esophagitis, and how the company thinks about other uses.
Co-Founder and CEO Jeffrey Finer describes how Septerna is able to screen for GPCR targets in ways that have not previously been possible. Plus, an overview of programs targeting MRGPRX2, PTH1R, and a collaboration with
He discusses Tyra, Sionna, Alumis, Nuvalent, and Monopar.
Robert Allen
American rocker · Fort Worth Economic Development Partnership
1 appearance on this show
Peter Hotez
professor of pediatrics and molecular virology · Baylor College of Medicine
1 appearance on this show
John Cox
The Voice of the Golden Eagles · Roost Booster Painting and Remodeling
1 appearance on this show
John Butler
Board Chair of Atlanta Vietnam Veterans Business Association · Bloomberg Intelligence
1 appearance on this show
Ian Smith
guest conductor of Bedford Sinfonia and conductor of Bedford Choral Society · National Outdoor Leadership School
1 appearance on this show
Tom Miller
former Deputy District Attorney · Ballard County, Kentucky
1 appearance on this show
Dr. Arun Swaminathan
CEO · Coya Therapeutics
1 appearance on this show
Michael Henderson
CEO · Apogee Therapeutics
1 appearance on this show
Jason Cole
hypermobility specialist · Future Standard
1 appearance on this show
Sponsor detection runs nightly. Check back soon.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
To pitch BiotechTV - News, visit https://podcasters.spotify.com/pod/show/biotechtv4 for contact information, then craft a tight one-paragraph hook that ties your expertise to a gap in their recent science coverage.
BiotechTV - News is hosted by BiotechTV. The show is categorised under science (life) and has published 429 episodes.
BiotechTV - News has published 429 episodes.
BiotechTV - News regularly covers science, life. It sits in the science category, with a life focus.
BiotechTV - News is accessible for guests with genuine science expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
BiotechTV - News hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of BiotechTV - News average 16 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates BiotechTV - News's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched 9 days ago.
